Treating acute ischemic stroke

UMMS Affiliation

Department of Neurology

Publication Date


Document Type



Animals; Brain Ischemia; Cerebrovascular Circulation; Diagnostic Imaging; Drug Administration Schedule; Equipment Design; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Neuroprotective Agents; Stroke; Thrombectomy; *Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome


Neurology | Neuroscience and Neurobiology


Acute ischemic stroke (AIS) is a common disorder that has only one associated approved therapy: intravenous tissue plasminogen activator (iv t-PA). A limiting factor to the use of iv t-PA is that it must be initiated within 3 h of stroke onset. Efforts to expand the therapeutic time window are underway and include image evaluation of the ischemic penumbra to target those patients who are most appropriate for treatment. Intra-arterial t-PA is also used only in some treatment centers despite convincing proof of efficacy of this therapy. Devices to restore perfusion that have been approved in the US for recanalization exist, but these are not approved for use in stroke therapy. Many neuroprotective drugs have been evaluated as potential acute stroke therapies, but none have shown efficacy, hence the future of neuroprotection as a strategy for acute ischemic stroke therapy remains uncertain.


Curr Opin Drug Discov Devel. 2008 Sep;11(5):626-32.

Journal/Book/Conference Title

Current opinion in drug discovery and development

Related Resources

Link to Article in PubMed

PubMed ID